Author

Giuseppe Lucisano

Observed name: Lucisano, G

Institutions: Center for Outcomes Research and Clinical Epidemiology, University of Bari Aldo Moro

Observed institutions: Mario Negri Sud Foundation, Center for Outcomes Research and Clinical Epidemiology, University of Bari Aldo Moro

ORCID: 0000-0003-3787-5241

Observed ORCID: 0000-0003-3787-5241

OpenAlex ID: A5101473237

Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies

2021 · Pietro Iaffaldano, Giuseppe Lucisano, et al. · Therapeutic Advances in Neurological Disorders · 124

PDF

Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis

2020 · Maria Pia Amato, Mattia Fonderico, et al. · Brain · 90

PDF

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

2015 · Pietro Iaffaldano, Giuseppe Lucisano, et al. · Brain · 84

PDF

Prognostic indicators in pediatric clinically isolated syndrome

2017 · Pietro Iaffaldano, Marta Simone, et al. · Annals of Neurology · 53

PDF

Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation

2015 · Giampiero Porcu, Eliseo Serone, et al. · PLoS ONE · 46

PDF

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Potential Diagnostic Biomarkers in Autism Spectrum Disorders: A Preliminary Study

2023 · Marta Simone, Andrea De Giacomo, et al. · International Journal of Molecular Sciences · 31

PDF

Big Multiple Sclerosis Data network: an international registry research network

2024 · Anna Glaser, Helmut Butzkueven, et al. · Journal of Neurology · 15

PDF

Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort

2019 · Alessia Manni, Antonio Iaffaldano, et al. · Frontiers in Immunology · 14

PDF

Characterization of the rs2802292 SNP identifies FOXO3Aas a modifier locus predicting cancer risk in patients with PJS and PHTS hamartomatous polyposis syndromes

2014 · Giovanna Forte, Valentina Grossi, et al. · BMC Cancer · 14

PDF

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study)

2026 · Damiano Paolicelli, Giuseppe Lucisano, et al. · Multiple Sclerosis Journal

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis

2026 · Nail Benallegue, Fabien Rollot, et al. · Multiple Sclerosis Journal

HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS

2026 · Tommaso Guerra, Giuseppe Lucisano, et al. · Journal of Neurology

PDF

Ten-year comparison of disability trajectories in multiple sclerosis patients treated with early intensive and escalation approach: a study from the Italian MS Register

2023 · Iaffaldano, P, Lucisano, G, et al. · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele

Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients

2021 · Pietro Iaffaldano, Giuseppe Lucisano, et al. · Journal of the Neurological Sciences

Front & Back Matter

2013 · Andrea Takeda, Olga P. Nyssen, et al. · Neuroepidemiology

Works count: 15

Citation count: 471

H-index: 9

I10-index: 9